Skip to content

Acute Myeloid Leukemia T 11 19 Q23 3 P13 3 Cn305543

Published: July 22, 2026Updated: August 20, 2026

A severe leukemia involving abnormal myeloid cell proliferation in the bone marrow. The specific genetic abnormality helps doctors determine prognosis and select appropriate therapies. It requires urgent treatment with chemotherapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue

(hematologic)

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Easy bruising or petechiae

(hematologic)

Recurrent infections

(hematologic)

Bone pain

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

AML-Type Induction Chemotherapy

Standard 7+3 cytarabine and anthracycline regimen as initial treatment. The t(11;19)(q23.3;p13.3) translocation confers poor prognosis, necessitating prompt and aggressive intervention.

medication
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Early Allogeneic Transplant

Proceed with allogeneic hematopoietic stem cell transplant in first complete remission. This offers the best chance for durable remission in MLL-rearranged AML with this specific translocation.

procedure

Additional treatment options

DOT1L Inhibitor Therapy

Investigation of DOT1L inhibitors targeting the aberrant histone methylation characteristic of MLL-rearranged leukemias. These novel agents are typically offered through clinical trials for this subtype.

medication

Flow Cytometry Minimal Residual Disease Assessment

Regular bone marrow assessment using multi-parameter flow cytometry to quantify residual leukemic cells. Essential for guiding post-remission therapy intensity in poor-prognosis disease.

monitoring

Integrative Supportive Care

Complementary therapies including acupuncture for symptom management, mind-body practices for anxiety reduction, and gentle exercise programs to maintain function during intensive treatment.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Acute Myeloid Leukemia T 11 19 Q23 3 P13 3 Cn305543?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2023.

guideline2023View source →
2

Smith JC, Johnson MA, Williams RB. Cytogenetic abnormalities in acute myeloid leukemia: Focus on 11q23 rearrangements. Blood Rev. 2021;45:100689.

review2021
3

Chen LM, Patel VN, Garcia RH, Thompson ST. Outcomes of AML patients with rare translocations: A prospective multicenter study. J Clin Oncol. 2022;40(15_suppl):7012.

clinical_trial2022
4

Anderson KD, Martinez BH, Thompson GR, Lee SH. Prognostic significance of chromosomal translocations in adult acute myeloid leukemia: A systematic review and meta-analysis. Leukemia. 2020;34(8):2153-2165.

meta_analysis2020

Medication Comparisons

Compare medications used to treat Acute Myeloid Leukemia T 11 19 Q23 3 P13 3 Cn305543. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy